TABLE 3.

Current treatment in polydrug dependence.

No	Reference	Drug name	Design of study	Number of patients	Drug administration	Dosage	Duration of study	Mechanism of action	Results	Conclusion
1	Tiihonen et al. (2012)	Naltrexone	Randomized, double blind, placebo controlled trial	100	Subcutaneous	1,000 mg naltrexone	10 weeks	Opioid receptor antagonist	Relative to placebo, the naltrexone implant resulted in higher retention in the study, decreased heroine and amphetamine use and improved clinical condition of patients	Naltrexone implant acts as an effective pharmacological treatment for this type of polydrug dependence
2	Downey et al. (2000)	Contigency managemtent with buprenorphine maintenance	—	41 (Mean age 40 years old, 25 male)	—	—	12 weeks	—	Results indicated that treatment produced significant reductions in drug problems over time, but there were no significant difference among treatment conditions	Hypothesis that voucher based reinforcement therapy would promote enhanced polydrug abstinence was not supported